

June 29, 2021

The Secretary Listing Department, BSE Limited, 1 <sup>st</sup> Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform that Aster DM Healthcare Limited ('the Company') has entered into a share purchase agreement with Hindustan Drug House, a partnership firm registered under the Partnership Act, 1932, which is in process of converting into a private limited company. The Company shall invest in 86% of the paid-up equity share capital of the converted private limited company.

The details required as per circular number CIR/CFD/CMD/4/2015 dated September 09, 2015 pertaining to continuous disclosure requirements for listed entities under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been enclosed as **Annexure I**.

We request you to kindly take the above information on record.

Thank You.

**For Aster DM Healthcare Limited**



**Puja Aggarwal**  
**Company Secretary and Compliance Officer**

**Annexure-I**

SI No	Particulars	
1	Name of the target entity, details in brief such as size, turnover etc.;	Hindustan Drug House i. Partner's Capital: INR 1.51 Crores  ii. Proposed Investment: Hindustan Drug House, a partnership firm is in the process of converting into a private limited company. Aster DM Healthcare Limited ('the Company') shall invest in 86% of the paid-up equity share capital of the converted private limited company.  ii. Turnover for FY 2019-20: INR 68.4 Crores
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Promoter/Promoter Group/Group Companies do not have any interest in the proposed investment
3	Industry to which the entity being acquired belongs;	Pharmaceutical distribution / trading
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To expand business into the growing pharmaceutical distribution segment by establishing supply chain and distribution network to sell into channels such as retail pharmacies, online pharmacies, hospitals and clinics
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable
6	Indicative time period for completion of the acquisition	75 days
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
8	Cost of acquisition or the price at which the shares are acquired;	Approximately INR 16.7 Crores
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Acquisition of equity shares resulting in acquiring 86% stake in the target company.

<p>10</p>	<p>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</p>	<p><b>About the entity:</b> Hindustan Drug House, a partnership firm registered under the Indian Partnership Act, 1932 with the Registrar of Firms, Basavanagudi, Bangalore bearing registration number 'FIRM/BSD/428/2017-18', having its place of business at No. 76/1, 2<sup>nd</sup> Floor, Arun Complex, Above Corporation Bank, J.C. Road, Bangalore-560002. It has been in operations for more than 50 years.</p> <p><b>Line of Business:</b> Whole-sale, supply and distribution of pharmaceutical products.</p> <p><b>Date of partnership agreement:</b> April 1, 2014</p> <p><b>Last 3 years Turnover:</b> FY 2019-20- INR 68.4 Crs  FY 2018-19- INR 67.4 Crs  FY 2017-18- INR 68.2 Crs</p>
-----------	--	---